Nav: Home

Low-grade brain tumors: Radiation plus chemotherapy is best treatment, trial suggests

April 14, 2016

COLUMBUS, Ohio - New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone.

The study, published in the New England Journal of Medicine, comes from a randomized phase III clinical trial (ClinicalTrials.gov number NCT00003375) of 251 people with grade 2 gliomas, tumors that occur mostly in young adults and cause progressive neurological problems and premature death. Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helped lead the study.

Patients treated with radiation therapy plus chemotherapy had an overall survival of 13.3 years compared with 7.8 years for patients treated with radiation alone. The radiation-plus-chemotherapy group also showed better disease-free survival (10.4 years versus 6.1 years for those treated with radiation alone).

In addition, patients with tumor cells having a mutation in a gene called IDH1 had significantly better overall survival than those without the mutation, regardless of treatment (13.1 years versus 5.1 years).

"This is a practice-changing study," says Arnab Chakravarti, MD, chair and professor of Radiation Oncology and director of the Brain Tumor Program at the OSUCCC - James. Chakravarti is the trial's translational research national study chair.

"These findings show that this combined radiation and chemotherapy regimen improves clinical outcome compared to radiation alone.

Chakravarti's lab was instrumental in validating IDH1 as a prognostic biomarker during the trial. "Furthermore, trends in the data suggest that IDH1 could be a useful predictive biomarker to identify glioma patients who would benefit from chemotherapy plus radiation therapy versus radiation therapy alone. These are immensely impactful findings of this phase III study," he says.

(Predictive biomarkers help predict a patient's response to a particular therapy; prognostic biomarkers help predict survival regardless of the therapy used.)

"Many low-grade gliomas progress to much more lethal grade III and IV tumors over time, so identifying the most effective treatment strategy is critical to ensure that patients have the best outcomes," says Chakravarti, who is also the Max Morehouse Chair in Cancer Research at Ohio State.

Low-grade gliomas represent less than 1 percent of all human tumors in the United States. The average survival times vary depending on the tumor's structural, molecular and genetic features.

The trial, which was sponsored by the Radiation Therapy Oncology Group, enrolled patients from 1998 to 2002. Median follow-up time for surviving patients was 11.9 years. About half the patients were treated with radiation therapy plus three chemotherapy drugs: procarbazine, lomustine (also called CCNU) and vincristine.

The study's key findings:

-end-
Other researchers involved in this study were Erica H. Bell, PhD, The Ohio State University; Jan C. Buckner, MD, Mayo Clinic, Rochester, MN; Edward G. Shaw, MD, Wake Forest University; Dennis Bullard, MD, Triangle Neurosurgeons, Raleigh; Stephanie L. Pugh, PhD, and Minhee Won, MA, NRG Oncology Statistics and Data Management Center; John H. Suh, MD, Cleveland Clinic; Mark R. Gilbert, MD, and Paul D. Brown, MD, of MD Anderson Cancer Center; Geoffrey R. Barger, MD, and Harold Kim, MD, Wayne State University; Stephen Coons, MD, Barrow Neurological Institute; David Brachman, MD, Arizona Oncology Services Foundation; Peter Ricci, MD, Radiology Imaging Associates, Englewood, CO; Keith Stelzer, MD, Mid-Columbia Medical Center, The Dalles, OR; Christopher J. Schultz, MD, Medical College of Wisconsin; Jean?Paul Bahary, MD, Centre Hospitalier de l'Université de Montréal, Montreal; Barbara J. Fisher, MD, London Regional Cancer Program, London, ON; Albert D. Murtha, MD, the Cross Cancer Institute, Edmonton, AB; Minesh P. Mehta, MD, University of Maryland; and Walter J. Curran Jr., MD, Emory University.

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 45 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 306-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.

Ohio State University Wexner Medical Center

Related Chemotherapy Articles:

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.
Male fertility after chemotherapy: New questions raised
Professor Delbès, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.
'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.
Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.
Chemotherapy or not?
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how 'smart' diagnostic-imaging machines identify cancers -- and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.
Researchers use radiomics to predict who will benefit from chemotherapy
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will respond to chemotherapy, according to a new study.
How drugs can minimize the side effects of chemotherapy
Researchers at the University of Zurich have determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy.
More Chemotherapy News and Chemotherapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.